AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month mortality
Number of subjects: 263
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale Extended (GOSE)
Number of subjects: 263
Study 38263321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally once a day and durvalumab 1500 mg once every 3 weeks
Number of subjects: 0
Study 38263353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (≥ 30 mg); median exposure: 169 days in placebo-controlled cohort, 624 days in all-exposure cohort.
Number of subjects: 1294
Study 38263353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (≥ 30 mg); median exposure: 624 days in all-exposure cohort.
Number of subjects: 1294
Study 38263353 — intervention group
Group type: COMPARATOR
Intervention: Placebo; median exposure: 169 days in placebo-controlled cohort.
Number of subjects: 1294
Study 38263486 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR BATs (anti-CD3 x anti-EGFR bispecific antibody armed T cells) in combination with radiation and temozolomide (TMZ)
Number of subjects: 0
Study 38263486 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR BATs at the maximum feasible dose of 80 × 10
Number of subjects: 0
Study 38263652 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous iscalimab (3 mg/kg)
Number of subjects: 82
Study 38263652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (10 mg/kg)
Number of subjects: 82
Study 38263652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 38263964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic infection management
Number of subjects: 0
Study 38263993 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived social support (PSS)
Number of subjects: 0
Study 38263993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower perceived social support (PSS)
Number of subjects: 0
Study 38263993 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable moderate-to-high PSS (3.98 on a scale of 1 to 5)
Number of subjects: 0
Study 38264276 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mcg norepinephrine
Number of subjects: 155
Study 38264276 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mcg norepinephrine
Number of subjects: 155
Study 38264323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 795
Study 38264323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795
Study 38264323 — intervention group
Group type: EXPERIMENTAL
Intervention: Background antipsychotic
Number of subjects: 795
Study 38264360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 255
Study 38264360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 255
Study 38264365 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education Program (DiPEP)
Number of subjects: 291
Study 38264365 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 291
Study 38264520 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide as first line treatment for mCRPC
Number of subjects: 68
Study 38264520 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 68
Study 38264520 — intervention group
Group type: EXPERIMENTAL
Intervention: ARv7 detection
Number of subjects: 68
Study 38264632 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of oral psilocybin (first dose: 25 mg; second dose: 25 or 30 mg) paired with non-directive support
Number of subjects: 30
Study 38264632 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 38264697 — intervention group
Group type: EXPERIMENTAL
Intervention: CURATE.AI-assisted dose titration
Number of subjects: 45
Study 38264697 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring (active control; HBPM)
Number of subjects: 45
Study 38264697 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 45
Study 38264861 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 243
Study 38264861 — intervention group
Group type: COMPARATOR
Intervention: Non-specific treatments (tranexamic acid or placebo ± prothrombin complex concentrate)
Number of subjects: 243
Study 38264861 — intervention group
Group type: COMPARATOR
Intervention: Non-specific treatments
Number of subjects: 243
Study 38264869 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucosopasem 100 mg
Number of subjects: 0
Study 38264869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38264938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated catheter-directed thrombolysis (USCDT) with mean alteplase (r-tPA) infusion duration of 10.5 hours and mean total r-tPA dose of 18.1 mg.
Number of subjects: 489
Study 38265029 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (prescribed to 30.8% of children)
Number of subjects: 266
Study 38265029 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (not prescribed to 69.2% of children)
Number of subjects: 266
Study 38265318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 19
Study 38265318 — intervention group
Group type: COMPARATOR
Intervention: Passive orthostasis
Number of subjects: 19
Study 38265436 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction-type lymphatic vessels (LVs)
Number of subjects: 83
Study 38265436 — intervention group
Group type: COMPARATOR
Intervention: Noncontraction-type lymphatic vessels (LVs)
Number of subjects: 83
Study 38265467 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD with suicidality
Number of subjects: 39
Study 38265467 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD without suicidality
Number of subjects: 39
Study 38265467 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 39
Study 38265633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 1485
Study 38265633 — intervention group
Group type: COMPARATOR
Intervention: Axitinib
Number of subjects: 1485
Study 38265781 — intervention group
Group type: EXPERIMENTAL
Intervention: REThink Online System (gamified assessment)
Number of subjects: 0
Study 38265781 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38265815 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 311
Study 38265815 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 311
Study 38265835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg, once daily)
Number of subjects: 1151
Study 38265835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1151
Study 38265847 — intervention group
Group type: EXPERIMENTAL
Intervention: WayToServe training and WayToServe Plus
Number of subjects: 180
Study 38265847 — intervention group
Group type: COMPARATOR
Intervention: WayToServe training only
Number of subjects: 180
Study 38266104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (CSF-1R inhibitor)
Number of subjects: 47
Study 38266104 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab (anti-PD-L1)
Number of subjects: 47
Study 38266154 — intervention group
Group type: EXPERIMENTAL
Intervention: efmoroctocog alfa (rFVIIIFc)
Number of subjects: 0
Study 38266154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-titer inhibitor progression to high-titer inhibitor
Number of subjects: 0
Study 38266332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety and obsessive-compulsive disorders, 12 sessions
Number of subjects: 27
Study 38266332 — intervention group
Group type: COMPARATOR
Intervention: Behavioral and self-report measures of SFA
Number of subjects: 27
Study 38266482 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trigger LH levels < 22 IU/L
Number of subjects: 224
Study 38266482 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal LH levels < 4 IU/L
Number of subjects: 224
Study 38266482 — intervention group
Group type: COMPARATOR
Intervention: Post-trigger LH levels above 15 IU/L
Number of subjects: 224
Study 38266575 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateropulsion attenuation
Number of subjects: 106
Study 38266683 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast (20 or 30 mg BID based on weight)
Number of subjects: 245
Study 38266683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 38266683 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 245
Study 38267024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAC)
Number of subjects: 61
Study 38267024 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider involvement
Number of subjects: 61
Study 38267024 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient knowledge and psychological factors
Number of subjects: 61
Study 38267024 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, patient-centred approach
Number of subjects: 61
Study 38267096 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE infection
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: CSE infection
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: Non-infected patients
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: CRE infection vs CSE infection
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: CRE infection vs Non-infected patients
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: CRE infection vs CSE infection (after adjustment)
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: CRE infection vs Non-infected patients (after adjustment)
Number of subjects: 1175
Study 38267096 — intervention group
Group type: COMPARATOR
Intervention: CRE infection vs CSE infection (with treatment-related variables)
Number of subjects: 1175
Study 38267105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical synovitis resolution
Number of subjects: 90
Study 38267105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical synovitis persistence
Number of subjects: 90
Study 38267105 — intervention group
Group type: EXPERIMENTAL
Intervention: Good prognostic factors for resolution
Number of subjects: 90
Study 38267105 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 90
Study 38267108 — intervention group
Group type: EXPERIMENTAL
Intervention: M/T FDC
Number of subjects: 187
Study 38267108 — intervention group
Group type: COMPARATOR
Intervention: macitentan
Number of subjects: 187
Study 38267108 — intervention group
Group type: COMPARATOR
Intervention: tadalafil
Number of subjects: 187
Study 38267144 — intervention group
Group type: EXPERIMENTAL
Intervention: IVI-guided PCI
Number of subjects: 4611
Study 38267144 — intervention group
Group type: EXPERIMENTAL
Intervention: Present IVI-guided PCI
Number of subjects: 4611
Study 38267144 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 4611
Study 38267149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of QRF area and thickness
Number of subjects: 143
Study 38267149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of QRF thickness
Number of subjects: 143
Study 38267149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of QRF area
Number of subjects: 143
Study 38267188 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenzocimab 1000 mg
Number of subjects: 166
Study 38267188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 38267220 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot length measurement (FL) with a cut-off of ≤7.6 cm
Number of subjects: 336
Study 38267220 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot length measurement (FL) with a cut-off of ≤7.5 cm
Number of subjects: 336
Study 38267239 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) combined with supervised exercise
Number of subjects: 184
Study 38267239 — intervention group
Group type: COMPARATOR
Intervention: Time-restricted eating (TRE) alone
Number of subjects: 184
Study 38267239 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise alone
Number of subjects: 184
Study 38267239 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study 38267243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose infusion
Number of subjects: 0
Study 38267243 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous succinate
Number of subjects: 0
Study 38267245 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) at a dose of 7.5 J/cm²
Number of subjects: 60
Study 38267245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health education (mHealth)
Number of subjects: 60
Study 38267245 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 60
Study 38267330 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine (PCV20)
Number of subjects: 1421
Study 38267330 — intervention group
Group type: COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 1421
Study 38267330 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPSV23)
Number of subjects: 1421
Study 38267330 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 1421
Study 38267484 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide polygenic score for higher BMI
Number of subjects: 1210
Study 38267496 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Fc receptor inhibitors
Number of subjects: 62
Study 38267496 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement inhibitors
Number of subjects: 62
Study 38267496 — intervention group
Group type: COMPARATOR
Intervention: Industry-sponsored trials
Number of subjects: 62
Study 38267496 — intervention group
Group type: COMPARATOR
Intervention: Trials releasing results
Number of subjects: 62
Study 38267496 — intervention group
Group type: COMPARATOR
Intervention: Phase 3 trials
Number of subjects: 62
Study 38267533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI Mediterranean diet
Number of subjects: 160
Study 38267533 — intervention group
Group type: COMPARATOR
Intervention: High-GI Mediterranean diet
Number of subjects: 160
Study 38267603 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT® BIG
Number of subjects: 32
Study 38267603 — intervention group
Group type: COMPARATOR
Intervention: Progressive Structured Mobility Training
Number of subjects: 32
Study 38267634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 38267634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour subpopulations associated with favourable prognosis and trastuzumab sensitivity
Number of subjects: 0
Study 38267634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour subpopulation associated with poor prognosis and trastuzumab resistance
Number of subjects: 0
Study 38267692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 162
Study 38267692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 38267790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50-mg capsules
Number of subjects: 0
Study 38267790 — intervention group
Group type: COMPARATOR
Intervention: Ritlecitinib 100-mg capsules
Number of subjects: 0
Study 38267801 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive Escherichia coli disease (IED)
Number of subjects: 240
Study 38267801 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial resistance (AMR) rates of E. coli isolates
Number of subjects: 240
Study 38267837 — intervention group
Group type: EXPERIMENTAL
Intervention: Health systems-level intervention alone
Number of subjects: 33
Study 38267837 — intervention group
Group type: EXPERIMENTAL
Intervention: Health systems-level intervention combined with shared decision-making aid
Number of subjects: 33
Study 38267837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as standard care without the interventions)
Number of subjects: 33
Study 38267890 — intervention group
Group type: EXPERIMENTAL
Intervention: BENIT program
Number of subjects: 6
Study 38267889 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIMix (one-minute multi-contrast MRI)
Number of subjects: 15
Study 38267889 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIMix
Number of subjects: 15
Study 38267889 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 15
Study 38267889 — intervention group
Group type: COMPARATOR
Intervention: EPIMix and CT
Number of subjects: 15
Study 38267942 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol administered immediately after birth
Number of subjects: 0
Study 38267942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38267987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C) levels
Number of subjects: 20351
Study 38268013 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression screening using the Patient Health Questionnaire (PHQ-9)
Number of subjects: 101
Study 38268015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial information about subclinical atherosclerosis with personalized, colour-coded and age-related risk communication strategy and motivational conversation
Number of subjects: 1749
Study 38268043 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive remediation programme
Number of subjects: 66
Study 38268043 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 66
Study 38268101 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 74
Study 38268156 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (0.5 g three times per day)
Number of subjects: 140
Study 38268156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 38268156 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 140
Study 38268157 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397
Study 38268157 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397
Study 38268157 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg to 300 mg dose escalation)
Number of subjects: 397
Study 38268157 — intervention group
Group type: COMPARATOR
Intervention: Any secukinumab group
Number of subjects: 397
Study 38268157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 38268221 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vaginal and rectal microbiomes during the last trimester
Number of subjects: 30
Study 38268221 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal microbiome at birth
Number of subjects: 30
Study 38268221 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal microbiome 2-3 days postnatally
Number of subjects: 30
Study 38268221 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal microbiomes in infants delivered by cesarean section
Number of subjects: 30
Study 38268522 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 40
Study 38268525 — intervention group
Group type: EXPERIMENTAL
Intervention: On FI.RE. accelerated framework
Number of subjects: 76
Study 38268525 — intervention group
Group type: COMPARATOR
Intervention: Traditional OFR framework
Number of subjects: 76
Study 38268535 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 632
Study 38268678 — intervention group
Group type: EXPERIMENTAL
Intervention: Canteen menus targeted to the individuals' nutritional and sensory needs
Number of subjects: 22
Study 38268678 — intervention group
Group type: COMPARATOR
Intervention: Standardized meal evaluation forms
Number of subjects: 22
Study 38268752 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 mg QW for 12 weeks
Number of subjects: 0
Study 38268752 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg QW for 12 weeks
Number of subjects: 0
Study 38268752 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study 38268752 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg QW or Q2W for maintenance
Number of subjects: 0
Study 38268752 — intervention group
Group type: COMPARATOR
Intervention: Placebo for maintenance
Number of subjects: 0
Study 38269045 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized silicone digital orthoses plus specialized nurse-administered foot care
Number of subjects: 60
Study 38269045 — intervention group
Group type: COMPARATOR
Intervention: Specialized nurse-administered foot care (Control Group)
Number of subjects: 60
Study 38269049 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) therapy
Number of subjects: 281
Study 38269049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 38269252 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fasting glucose
Number of subjects: 105
Study 38269252 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 2-hour glucose
Number of subjects: 105
Study 38269269 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human annexin A5 (SY-005)
Number of subjects: 0
Study 38269269 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38269302 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 condition (PCC)
Number of subjects: 368
Study 38269302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild PCC
Number of subjects: 368
Study 38269302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized PCC
Number of subjects: 368
Study 38269302 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-PCC
Number of subjects: 368
Study 38269302 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 368